Dr. Rosenberg Discusses the Importance of Clinical Trials in Bladder Cancer

Partner | Cancer Centers | <b>Memorial Sloan Kettering Cancer Center </b>

Jonathan E. Rosenberg, MD, medical oncologist at Memorial Sloan Kettering Cancer Center, discusses the importance of referring patients to clinical trials in bladder cancer.

Jonathan E. Rosenberg, MD, medical oncologist at Memorial Sloan Kettering Cancer Center, discusses the importance of referring patients to clinical trials in bladder cancer.

There is a long history of failed adjuvant clinical trials in bladder cancer due to poor accrual, says Rosenberg. He says that is important for treating physicians to recommend patients for these trials in order to test novel adjuvant therapies.

Adjuvant immunotherapy trials are showing greater success in accrual though, Rosenberg adds.